On Friday, the FDA ruled that cancer drug Avastin should not be used to treat breast cancer because Avastin’s risky side-effects outweigh its benefits for breast cancer patients. “Women who take Avastin for metastatic breast cancer risk potentially life threatening or serious side-effects, such as heart attacks or heart failure, severe high blood pressure, bleeding or hemorrhaging,” FDA Commissioner Dr. Margaret Hamburg said. Avastin still has FDA approval for treating lung, kidney, and colon cancer, and despite the ruling, Medicare will still cover Avastin for breast cancer patients. Joe Nocera, op-ed columnist for The New York Times, argues that the FDA made the right decision.
At The World, we believe strongly that human-centered journalism is at the heart of an informed public and a strong democracy. We see democracy and journalism as two sides of the same coin. If you care about one, it is imperative to care about the other.
Every day, our nonprofit newsroom seeks to inform and empower listeners and hold the powerful accountable. Neither would be possible without the support of listeners like you. If you believe in our work, will you give today? We need your help now more than ever!